In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Berna Biotech buys Rhein Biotech in $257mm cash/stock deal

Executive Summary

Switzerland-based Berna Biotech (serums/vaccines for treating infectious diseases) is acquiring 4.05mm shares of Dutch vaccine developer Rhein Biotech for about $257mm (Euro277mm) in cash and stock--or over three times Rhein's 2001 sales revenue of $76.3mm.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Intra-Biotech Deal
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies